-
Je něco špatně v tomto záznamu ?
Morphine Analgesia, Cannabinoid Receptor 2, and Opioid Growth Factor Receptor Cancer Tissue Expression Improve Survival after Pancreatic Cancer Surgery
L. Vecera, P. Prasil, J. Srovnal, E. Berta, M. Vidlarova, T. Gabrhelik, P. Kourilova, M. Lovecek, P. Skalicky, J. Skarda, Z. Kala, P. Michalek, M. Hajduch
Status neindexováno Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
NV18-03-00470
Ministry of Health
BBMRI - LM2018125, NCMG - LM2023067, EATRIS-CZ - LM2018133
Ministry of Youth and Sports
Programme EXCELES, ID Project No. LX22NPO5102
European Union - Next Generation EU
LF 2023_006
Palacky University Olomouc
Free Medical Journals od 2009
PubMed Central od 2009
Europe PubMed Central od 2009
ProQuest Central od 2009-01-01
Open Access Digital Library od 2009-01-01
Open Access Digital Library od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources od 2009
Odkazy
PubMed
37627066
DOI
10.3390/cancers15164038
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Pancreatic cancer (PDAC) has a poor prognosis despite surgical removal and adjuvant therapy. Additionally, the effects of postoperative analgesia with morphine and piritramide on survival among PDAC patients are unknown, as are their interactions with opioid/cannabinoid receptor gene expressions in PDAC tissue. Cancer-specific survival data for 71 PDAC patients who underwent radical surgery followed by postoperative analgesia with morphine (n = 48) or piritramide (n = 23) were therefore analyzed in conjunction with opioid/cannabinoid receptor gene expressions in the patients' tumors. Receptor gene expressions were determined using the quantitative real-time polymerase chain reaction. Patients receiving morphine had significantly longer cancer-specific survival (CSS) than those receiving piritramide postoperative analgesia (median 22.4 vs. 15 months; p = 0.038). This finding was supported by multivariate modelling (p < 0.001). The morphine and piritramide groups had similar morphine equipotent doses, receptor expression, and baseline characteristics. The opioid/cannabinoid receptor gene expression was analyzed in a group of 130 pancreatic cancer patients. Of the studied receptors, high cannabinoid receptor 2 (CB2) and opioid growth factor receptor (OGFR) gene expressions have a positive influence on the length of overall survival (OS; p = 0.029, resp. p = 0.01). Conversely, high delta opioid receptor gene expression shortened OS (p = 0.043). Multivariate modelling indicated that high CB2 and OGFR expression improved OS (HR = 0.538, p = 0.011, resp. HR = 0.435, p = 0.001), while high OPRD receptor expression shortened OS (HR = 2.264, p = 0.002). Morphine analgesia, CB2, and OGFR cancer tissue gene expression thus improved CSS resp. OS after radical PDAC surgery, whereas delta opioid receptor expression shortened OS.
Cancer Research Czech Republic Foundation 779 00 Olomouc Czech Republic
Department of Anaesthesia and Intensive Care Ringerike Hospital 3511 Hønefoss Norway
Department of Anesthesiology and Intensive Medicine Landesklinikum Amstetten 3300 Amstetten Austria
Department of Emergency Medicine The Tomas Bata Regional Hospital in Zlin 762 75 Zlin Czech Republic
Laboratory of Experimental Medicine Olomouc University Hospital 779 00 Olomouc Czech Republic
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23015497
- 003
- CZ-PrNML
- 005
- 20231020093446.0
- 007
- ta
- 008
- 231010s2023 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/cancers15164038 $2 doi
- 035 __
- $a (PubMed)37627066
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Vecera, Lubomir $u Department of Emergency Medicine, The Tomas Bata Regional Hospital in Zlin, 762 75 Zlin, Czech Republic $u Department of Paediatric Anaesthesiology and Intensive Care Medicine, University Hospital Brno, Medical Faculty of Masaryk University, 625 00 Brno, Czech Republic
- 245 10
- $a Morphine Analgesia, Cannabinoid Receptor 2, and Opioid Growth Factor Receptor Cancer Tissue Expression Improve Survival after Pancreatic Cancer Surgery / $c L. Vecera, P. Prasil, J. Srovnal, E. Berta, M. Vidlarova, T. Gabrhelik, P. Kourilova, M. Lovecek, P. Skalicky, J. Skarda, Z. Kala, P. Michalek, M. Hajduch
- 520 9_
- $a Pancreatic cancer (PDAC) has a poor prognosis despite surgical removal and adjuvant therapy. Additionally, the effects of postoperative analgesia with morphine and piritramide on survival among PDAC patients are unknown, as are their interactions with opioid/cannabinoid receptor gene expressions in PDAC tissue. Cancer-specific survival data for 71 PDAC patients who underwent radical surgery followed by postoperative analgesia with morphine (n = 48) or piritramide (n = 23) were therefore analyzed in conjunction with opioid/cannabinoid receptor gene expressions in the patients' tumors. Receptor gene expressions were determined using the quantitative real-time polymerase chain reaction. Patients receiving morphine had significantly longer cancer-specific survival (CSS) than those receiving piritramide postoperative analgesia (median 22.4 vs. 15 months; p = 0.038). This finding was supported by multivariate modelling (p < 0.001). The morphine and piritramide groups had similar morphine equipotent doses, receptor expression, and baseline characteristics. The opioid/cannabinoid receptor gene expression was analyzed in a group of 130 pancreatic cancer patients. Of the studied receptors, high cannabinoid receptor 2 (CB2) and opioid growth factor receptor (OGFR) gene expressions have a positive influence on the length of overall survival (OS; p = 0.029, resp. p = 0.01). Conversely, high delta opioid receptor gene expression shortened OS (p = 0.043). Multivariate modelling indicated that high CB2 and OGFR expression improved OS (HR = 0.538, p = 0.011, resp. HR = 0.435, p = 0.001), while high OPRD receptor expression shortened OS (HR = 2.264, p = 0.002). Morphine analgesia, CB2, and OGFR cancer tissue gene expression thus improved CSS resp. OS after radical PDAC surgery, whereas delta opioid receptor expression shortened OS.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Prasil, Petr $u Department of Anesthesiology and Intensive Medicine, Landesklinikum Amstetten, 3300 Amstetten, Austria
- 700 1_
- $a Srovnal, Josef $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic $u Laboratory of Experimental Medicine, Olomouc University Hospital, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Berta, Emil $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic $u Department of Anaesthesia and Intensive Care, Ringerike Hospital, 3511 Hønefoss, Norway
- 700 1_
- $a Vidlarova, Monika $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic $u Laboratory of Experimental Medicine, Olomouc University Hospital, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Gabrhelik, Tomas $u Department of Anaesthesiology, Resuscitation and Intensive Care, The Tomas Bata Regional Hospital in Zlin, 762 75 Zlin, Czech Republic
- 700 1_
- $a Kourilova, Pavla $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic $u Laboratory of Experimental Medicine, Olomouc University Hospital, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Lovecek, Martin $u Department of Surgery I, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000197759643 $7 xx0078672
- 700 1_
- $a Skalicky, Pavel $u Department of Surgery I, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Skarda, Jozef $u Institute of Molecular and Clinical Pathology and Medical Genetics, Faculty of Medicine, University Hospital Ostrava, University of Ostrava, 703 00 Ostrava, Czech Republic
- 700 1_
- $a Kala, Zdenek $u Department of Surgery, Faculty of Medicine, University Hospital Brno, Masaryk University, 625 00 Brno, Czech Republic
- 700 1_
- $a Michalek, Pavel $u Department of Anesthesiology and Intensive Medicine, General University Hospital, First Medical Faculty of the Charles University, 128 00 Prague, Czech Republic $1 https://orcid.org/0000000181195927 $7 xx0079908
- 700 1_
- $a Hajduch, Marian $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic $u Laboratory of Experimental Medicine, Olomouc University Hospital, 779 00 Olomouc, Czech Republic $u Cancer Research Czech Republic Foundation, 779 00 Olomouc, Czech Republic $1 https://orcid.org/000000024834908X $7 xx0050218
- 773 0_
- $w MED00173178 $t Cancers $x 2072-6694 $g Roč. 15, č. 16 (2023)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37627066 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231010 $b ABA008
- 991 __
- $a 20231020093439 $b ABA008
- 999 __
- $a ok $b bmc $g 1997161 $s 1201859
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2023 $b 15 $c 16 $e 20230809 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
- GRA __
- $a NV18-03-00470 $p Ministry of Health
- GRA __
- $a BBMRI - LM2018125, NCMG - LM2023067, EATRIS-CZ - LM2018133 $p Ministry of Youth and Sports
- GRA __
- $a Programme EXCELES, ID Project No. LX22NPO5102 $p European Union - Next Generation EU
- GRA __
- $a LF 2023_006 $p Palacky University Olomouc
- LZP __
- $a Pubmed-20231010